Injective (INJ) is currently trading at $5.75, reflecting a 4.17% increase over the past 24 hours. The asset has maintained its daily high of $5.75 while its low was recorded at $5.30, indicating a stable trading range of 0.45% within this period.

Trading volume has reached 66,817,217, corresponding to 11.63% of the market cap, which suggests robust market interest and liquidity. The hourly moving averages show positive momentum, with the 8 SMA at $5.53 (+4.04%) and the 21 SMA at $5.51 (+4.32%), indicating short-term bullish sentiment.

The 1-hour RSI is at 70, suggesting that INJ may be overbought in the very short term, which could lead to a price correction. Conversely, the 7-day RSI at 55 indicates that the asset is still within a neutral zone, allowing room for further upward movement without immediate overextension.

Over the past week, INJ has gained approximately 9.82%, reflecting a strong recovery from recent lows, while the 14-day price change stands at 5.63%. However, the 30-day price change shows a significant decline of 27.49%, indicating that while there is recent bullish momentum, the longer-term trend remains bearish.

The all-time high for INJ is $52.62, achieved in March 2024, showing significant upside potential from the current price level. Despite the recent gains, the substantial drop over the past month suggests a cautious approach is warranted.

Based on the current analysis, a Buy rating is recommended. The short-term momentum and trading volume indicate positive sentiment, and the relatively stable RSI levels support potential for further gains. However, investors should remain vigilant for any signs of reversal given the asset's recent volatility.